Looking for some blue chip additions to your portfolio? Listed below are a couple of ASX 200 blue chip shares that have been given buy ratings by analysts
Here's why its analysts rate them highly right now:
ResMed Inc. (ASX: RMD)
The first blue chip ASX 200 share that has been named as a buy is ResMed.
It is a medical device company with a focus on sleep treatment and respiratory products. These products treat disorders such as sleep apnoea and chronic obstructive pulmonary disease (COPD).
These certainly are great markets to be in. For example, in respect to the former, the company estimates that upwards of 1 in 5 people are believed to suffer from sleep apnoea.
And with the vast majority currently undiagnosed, this provides a significant long term growth runway. Particularly given its industry-leading products, high level of investment in research and development each year, and wide distribution network.
Goldman Sachs is bullish on ResMed. It currently has a buy rating and $36.80 price target on its shares. This compares to the latest ResMed share price of $32.04.
Treasury Wine Estates Ltd (ASX: TWE)
Another blue chip ASX 200 share that is highly rated is Treasury Wine. It the global wine giant behind a range of popular brands including Penfolds.
Treasury Wine certainly has been through a lot in recent years but has come out of it looking arguably stronger.
In fact, the team at Morgans believe "the foundations are now in place for TWE to deliver strong earnings growth" in the coming years.
In light of this, Morgans has named Treasury Wine as a "key pick" and put an add rating and $13.93 price target on its shares. This compares to the current Treasury Wine share price of $12.55.
